GSR real-world registry
With more than 3,000 patients enrolled, the
GLOBAL SYMPLICITY REGISTRY (GSR) is the largest
renal denervation (RDN) data set in the world.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
RDN Markus Schlaich Data Video - (11:08)
A Medtronic Renal Denervation (RDN) video covering Professor Markus Schlaich's presentation discussing Global Symplicity Registry data in patients with resistant hypertension (HTN), at the TCT 2020 conference as part of the latest interviews and symposia congress content on the videos and presentation page for Medtronic.
More information (see more) Less information (see less)
GSR DEFINE is a prospective, multi-center, single-arm, non-interventional and open-label registry that will document the long-term safety and efficacy of the Symplicity blood pressure procedure.
See which types of patients could beneft from the Symplicity blood pressure procedure.
Compared to a modeled control group in the GLOBAL SYMPLICITY REGISTRY.
2,000 incremental patients to the GLOBAL SYMPLICITY REGISTRY.
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.
Mahfoud F, Mancia G, Schmieder R, et. al. Renal Denervation in high-risk patients with hypertension. Journal of the American College of Cardiology. 2020; 75(23): 2879 - 2888.
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Subgroup Analysis. Presented at ESH 2019.
Schmieder R, Böhm M, Schlaich M, et al. Modeled Clinical Event Reductions at Three Years in High-Risk Hypertension Patients Treated with Renal Denervation. Presented at Deutsche Gesellschaft fur Kardiologie 2021.
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet 2020; Published online March 29, 2020.
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022; 399:1401-1410.